ArticleBMC cancer2015

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.

Zengjun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.